CORDIS · 101112145 · HORIZON
PROMINENT PRECISION MEDICINE PLATFORM IN NEURODEGENERATIVE DISEASE
Coordinator: KAROLINSKA INSTITUTET (SE)
Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Comorbidities with these conditions are frequent and a major obstacle to optimal diagnosis and management. Recent advances in diagnostic technologies and the advent of disease-modifying therapies (DMT) for Alzheimer’s disease (AD), the most common aetiology of dementia, heralds the beginning of precision medicine in this disease area. PROMINENT will develop a digital pl…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
Co-funding: the European Union contributes €6.1M toward a total project budget of €11.1M — a funding rate of 55%, with the remainder covered by the consortium partners. The project runs over approximately 5 years from 2023-05-01 to 2028-04-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from SE
see all →- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · FP7 · €109.4M
- GrapheneCore1 — Graphene-based disruptive technologies696656 · H2020 · €89.0M
- GrapheneCore2 — Graphene Flagship Core Project 2785219 · H2020 · €88.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · FP7 · €75.3M
- 2D-EPL — Graphene Flagship 2D Experimental Pilot Line952792 · H2020 · €20.0M
- BrightnESS — Building a research infrastructure and synergies for highest scientific impact on ESS676548 · H2020 · €19.9M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-JU-RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.1M toward a total project budget of €11.1M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-JU-IHI-2022-01-single-stage.
- Who coordinates the project?
- The project is coordinated by KAROLINSKA INSTITUTET (SE).
- What is the project timeline?
- The project runs from 2023-05-01 to 2028-04-30 — approximately 5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101112145.